IP Library Granted Patent US 11,167,047
Granted Patent B2
US 11,167,047 · App. 16/279,482 · Granted Nov 9, 2021

Coated plant virus imaging agents

Inventors: Nicole F. Steinmetz (San Diego, CA); Michael Bruckman (Cleveland, OH); Lauren Randolph (State College, PA)
Assignee: CASE WESTERN RESERVE UNIVERSITY
A61K49/1896A61K49/085A61K49/108
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,167,047
App. No.
16/279,482
Granted
Nov 9, 2021
Kind
B2
Abstract

An imaging nanoparticle comprising a plant virus particle having an interior surface and an exterior surface, an imaging agent that is linked to the interior and/or exterior surface, and a layer of biocompatible mineral such as silica coated over the exterior surface, is described. The imaging nanoparticle can be used in method of generating an image of a tissue region of a subject, by administering to the subject a diagnostically effective amount of an imaging nanoparticle and generating an image of the tissue region of the subject to which the imaging nanoparticle has been distributed.

Claims (21)

1. An imaging nanoparticle, comprising a rod-shaped plant virus particle having an interior surface and an exterior surface, a chelated lanthanide imaging agent that is linked to the interior, and a layer of biocompatible mineral coated over the exterior surface.

2. The imaging nanoparticle of claim 1 , wherein the biocompatible mineral is silica.

3. The imaging nanoparticle of claim 1 , wherein the rod-shaped virus belongs to the Virgaviridae family.

4. The imaging nanoparticle of claim 1 , wherein the rod-shaped virus is a tobacco mosaic virus.

5. The imaging nanoparticle of claim 1 , wherein the lanthanide is gadolinium.

6. The imaging nanoparticle of claim 5 , wherein the plant virus particles are selected from the group consisting of iGd-TMV-Si, eGd-TMV, eGd-TMV-Si, Gd-SNP, and Gd-SNP-Si, and wherein the plant virus particles have a relaxivity of greater than about 25,000 mM −1 S −1 per particle.

7. The imaging nanoparticle of claim 1 , wherein a targeting moiety is linked to the exterior surface of the virus particle.

8. The imaging nanoparticle of claim 7 , wherein the targeting moiety binds specifically to an immune cell.

9. The imaging nanoparticle of claim 1 , wherein at least about 500 imaging agent molecules are linked to the virus particle.

10. The method of claim 1 , wherein the biocompatible mineral increases the ionic relaxivity of the particles compared to a non-mineralized particle.

11. The method of claim 1 , wherein the biocompatible mineral reduces the immunogenicity of the particles when administered to a subject compared to a non-mineralized particle.

12. A method of generating an image of a tissue region of a subject, by administering to the subject a diagnostically effective amount of an imaging nanoparticle, comprising a rod shaped plant virus particle having an interior surface and an exterior surface, a chelated lanthanide imaging agent that is linked to the interior surface, and a layer of biocompatible mineral coated over the exterior surface, and generating an image of the tissue region of the subject to which the imaging nanoparticle has been distributed.

13. The method of claim 12 , wherein the biocompatible mineral is silica.

14. The method of claim 12 , wherein the rod shaped virus is a tobacco mosaic virus.

15. The method of claim 12 , wherein the method of generating an image is magnetic resonance imaging.

16. The method of claim 12 , wherein the imaging nanoparticle further comprises a targeting moiety is linked to the exterior surface of the virus particle.

17. The method of claim 16 , wherein the targeting moiety specifically binds to an immune cell.

18. The method of claim 12 , wherein the tissue region includes a blood vessel.

19. The method of claim 12 , wherein the plant virus particles are selected from the group consisting of iGd-TMV-Si, eGd-TMV, eGd-TMV-Si, Gd-SNP, and Gd-SNP-Si, and wherein the plant virus particles have a relaxivity of greater than about 25,000 mM −1 S −1 per particle.

20. The method of claim 12 , wherein the biocompatible mineral increases the ionic relaxivity of the particles compared to a non-mineralized particle.

21. The method of claim 12 , wherein the biocompatible mineral reduces the immunogenicity of the particles when administered to the subject compared to a non-mineralized particle.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2019
From: STEINMETZ, NICOLE F.; BRUCKMAN, MICHAEL; RANDOLPH, LAUREN
To: CASE WESTERN UNIVERSITY
Reel/Frame 049616/0596 →
Continuity (4)
Continuation 15937681 · Mar 27, 2018
Continuation 14818812 · Aug 5, 2015
Provisional Application 62033297 · Aug 5, 2014
Related Publication 20200384131A1 · Dec 10, 2020
Cited By (6)
US 12,203,073 US 12,359,175 US 12,433,840 US 12,433,955 US 12,465,624 US 12,599,141